Biolux Research, Vancouver, Canada, developer of OrthoPulse®, has announced renewal of its partnership with the Schulman Study Group. The partnership aims to promote and provide photobiomodulation products to Schulman orthodontic practices and patients.
Previously, members of the Schulman Study Group participated in a beta evaluation of OrthoPulse in the United States and Canada.
OrthoPulse is a medical device that uses low levels of light energy to stimulate the bone surrounding the roots of teeth and facilitate tooth movement, thus, according to the company, reducing treatment time. OrthoPulse® received FDA clearance in July 2015 and is cleared by the FDA for use with both braces and clear aligners.
The device is designed to be used by patients on a daily basis for a total of 10 minutes, either at home or while traveling. According to Biolux, clinical evidence acquired to date shows a significant reduction of treatment time for patients undergoing orthodontic treatment, and feedback from patients and doctors indicates that photobiomodulation helps to reduce discomfort typically experienced by orthodontic patients.
Membership to the Schulman Study Group is extended by invitation.
